Detected ·
AnaCardio
€62.5M—
Swedish clinical-stage biotech AnaCardio raised EUR 62.5M (USD 70.9M) in a Series B led by Novo Holdings and the Ljungström family office, with participation from Helsinn Group, Pureos Bioventures and Sound Bioventures, to advance its oral heart failure drug AC01 through Phase IIb development.
- Website
- www.anacardio.com
- linkedin.com/company/anacardio
- Amount
- €62 500 000 EUR
- Stage
- —
- Event
- Funding round
- Detected
- 2026-09-29 16:48:47 UTC
- Signal ID
- bf674d61-d447-4277-b7af-c4f8615e219c
As the API returns it
{
"id": "bf674d61-d447-4277-b7af-c4f8615e219c",
"created_at": "2026-09-29T16:48:47.607970Z",
"company_name": "AnaCardio",
"company_website_url": "www.anacardio.com",
"company_linkedin_url": "https://www.linkedin.com/company/anacardio",
"event_type": "funding",
"funding_amount": 62500000,
"funding_currency": "EUR",
"funding_stage": null,
"message": "*Swedish clinical-stage biotech AnaCardio raised EUR 62.5M (USD 70.9M) in a Series B led by Novo Holdings and the Ljungström family office, with participation from Helsinn Group, Pureos Bioventures and Sound Bioventures, to advance its oral heart failure drug AC01 through Phase IIb development.*"
}